CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation

被引:49
作者
Pittner, BT
Shanafelt, TD
Kay, NE
Jelinek, DF
机构
[1] Mayo Clin & Mayo Fdn, Dept Immunol, Coll Med, Mayo Grad Sch, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Hematol, Coll Med, Mayo Grad Sch, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Dept Internal Med, Coll Med, Mayo Grad Sch, Rochester, MN 55905 USA
关键词
B-CLL; CD38; interferon; cell activation; cell cycle;
D O I
10.1038/sj.leu.2403975
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD38, a surface protein whose expression increases upon normal B-cell activation, is a marker of disease aggression in B-cell chronic lymphocytic leukemia (B-CLL). Higher percentages of CD38-expressing CLL B cells may be found in lymphoid compartments compared to peripheral blood. Therefore, it is possible that although CLL B cells are resting, CD38 may be a marker of recent cell activation prior to entry into the periphery. To address this hypothesis, we examined the association of CD38 expression with other activation antigens identified in gene expression profiling experiments and include CD18, CD49d, CD20, and subunit 5 of the anaphase-promoting complex/cyclosome. We found that all these markers were more highly expressed in leukemic B cells from CD38-positive CLL patients. Lastly, because interferon is known to modulate CD38 expression, we used IFN-alpha to test the ability of CLL B cells to increase CD38 expression in vitro. Interestingly, IFN stimulation only modulated CD38 expression in CLL B cells that already expressed CD38. Taken together, these data suggest that CD38 is a marker of a more recently activated CLL B cell. This in turn may explain the biological and clinical differences between CD38-positive type B-CLL and CD38-negative type B-CLL.
引用
收藏
页码:2264 / 2272
页数:9
相关论文
共 40 条
[31]  
Musso T, 2001, J LEUKOCYTE BIOL, V69, P605
[32]  
POSTIGO AA, 1993, J IMMUNOL, V151, P2471
[33]   Integrins and T cell-mediated immunity [J].
Pribila, JT ;
Quale, AC ;
Mueller, KL ;
Shimizu, Y .
ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :157-180
[34]   Alterations of DNA methylation in hematologic malignancies [J].
Rush, LJ ;
Plass, C .
CANCER LETTERS, 2002, 185 (01) :1-12
[35]   MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation [J].
Stacchini, A ;
Aragno, M ;
Vallario, A ;
Alfarano, A ;
Circosta, P ;
Gottardi, D ;
Faldella, A ;
Rege-Cambrin, G ;
Thunberg, U ;
Nilsson, K ;
Caligaris-Cappio, F .
LEUKEMIA RESEARCH, 1999, 23 (02) :127-136
[36]   Co-ligation of surface IgM and CD40 on naive B lymphocytes generates a blast population with an ambiguous extrafollicular/germinal centre cell phenotype [J].
Wheeler, K ;
Gordon, J .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (06) :815-828
[37]   Whose end is destruction: cell division and the anaphase-promoting complex [J].
Zachariae, W ;
Nasmyth, K .
GENES & DEVELOPMENT, 1999, 13 (16) :2039-2058
[38]   CD38 SIGNALING BY AGONISTIC MONOCLONAL-ANTIBODY PREVENTS APOPTOSIS OF HUMAN GERMINAL CENTER B-CELLS [J].
ZUPO, S ;
RUGARI, E ;
DONO, M ;
TABORELLI, G ;
MALAVASI, F ;
FERRARINI, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (05) :1218-1222
[39]   CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis [J].
Zupo, S ;
Isnardi, L ;
Megna, M ;
Massara, R ;
Malavasi, F ;
Dono, M ;
Cosulich, E ;
Ferrarini, M .
BLOOD, 1996, 88 (04) :1365-1374
[40]   Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD [J].
Zupo, S ;
Massara, R ;
Dono, M ;
Rossi, E ;
Malavasi, F ;
Cosulich, ME ;
Ferrarini, M .
BLOOD, 2000, 95 (04) :1199-1206